 Q BioMed Inc has highlighted that its pre-clinical Uttroside-B chemotherapeutic to treat liver cancer has been found in a new study to show superior safety and efficacy compared to the current FDA approved drug Sorafenib. The publication in May this year was entitled Augmented Efficacy of Uttroside-B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma. 